Research programme: antibody-drug conjugates - UCB/Seagen
Alternative Names: cAC10-val-cit-MMAELatest Information Update: 18 Dec 2023
At a glance
- Originator Seattle Genetics; UCB
- Developer Seagen; UCB
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies; Immunological disorders